Total
0
Shares
Pharmaceutical dispensary
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • A new swathe of commonly used multiple sclerosis, diabetes and asthma treatments will be included under the Pharmaceutical Benefits Scheme (PBS)
  • Asthma treatment Atecture Breezhale and multiple sclerosis medication Zeposia will make their debuts under the scheme, potentially saving patients paying more than $400 and $29,000 per year, respectively
  • Type two diabetes treatment Trulicity will also have its tenure on the listing extended
  • Inclusions under the scheme follow recommendations by the independent Pharmaceutical Benefits Advisory Committee and are updated on the first day of every month

A new swathe of commonly used multiple sclerosis, diabetes and asthma treatments will be included under the Pharmaceutical Benefits Scheme (PBS).

The latest listings, which have been made available under the Australian government subsidy as of yesterday, are set to cover medications used by around 51,800 people across the country.

Asthma treatment Atecture Breezhaler and multiple sclerosis medication Zeposia will make their debut on the listing, while the Trulicity diabetes medicament will have its PBS tenure extended.

Both new additions, Atecture and Zeposia, will be available to patients at a heavily discounted price tag of $41.30 per script or $6.60 for those with a concession card.

Inclusions under the scheme follow recommendations by the independent Pharmaceutical Benefits Advisory Committee (PBAC) and are updated on the first day of every month.

According to the PBAC, it weighs up the medical and cost-effectiveness of a proposed benefit compared to alternative therapies and makes recommendations to the Minister regarding which should be subsidised under the PBS.

New and extended listings

The Atecture Breezhaler is typically used to aid those suffering with the effects of asthma, by relaxing and reducing swelling and irritation in the small airways of the lungs and could previously set back patients more than $400 per year.

The second new addition, Zeposia, is a treatment for relapsing remitting multiple sclerosis, a chronic disease that affects more than 25,600 people in Australia and currently has no cure.

Its new PBS price represents a significant discount on the $29,000 per year patients could spend on the medicament.

Lastly, the type two diabetes treatment Trulicity will have its time under the scheme extended, granting around 12,000 patients in Australia discounted access to the medication.

The Australian Government has approved more than 2550 new or amended listings on the PBS since 2013.

More From The Market Herald

" 1 in 3 current staff in federal parliament experienced sexual harassment: report

One in three federal parliament employees who responded to a review of the workplace culture of Parliament House say they have experienced some

" Perth industrial market going from strength to strength

The industrial market is the most sought-after commercial asset class in Australia at the moment, and Perth is no exception.

" ASX big caps join emissions reporting scheme as Australia reduces annual carbon output by 2.1pc

ASX big caps Coles (COL) and Woodside Petroleum (WPL) have joined 11 other large Australian businesses in getting behind the Federal Government’s recently-announced

" Macquarie Group (ASX:MQG) flags $2.2b regulatory hit

Macquarie Group (MQG) is anticipating a $2.2 billion hit to its capital surplus for after the financial regulator announced changes to the ban…